Glumate and Disorders of Cognition and Motivation

描述（由申请人提供）：尽管谷氨酸介导的神经传递长期以来与神经退行性疾病有关，但对认知、情感和成瘾性疾病的研究主要集中在大脑中的单胺（多巴胺、5-羟色胺、去甲肾上腺素）系统。由于谷氨酸在皮质功能中的重要性，并且由于谷氨酸能投射支配单胺能神经元的活动，因此关于谷氨酸在情感和成瘾性障碍中的可能作用的研究开始了10 - 15年，并且导致了我们对谷氨酸能参与这些障碍的理解的重大进展。纽约科学院将于2003年4月13日至15日在康涅狄格州纽黑文市主办一个为期2.5天的会议，题为"谷氨酸盐与认知和动机障碍"。会议的目的是汇集不同的基础和临床研究人员，他们研究谷氨酸盐在认知障碍如精神分裂症和与动机和情感有关的障碍中的作用，比如抑郁症和成瘾。本次会议将提供一个场地，介绍基础和临床领域的前沿研究。通过促进基础科学家和临床医生之间的互动，它可能会加快我们对基本机制的认识的进步转化为新药物疗法开发的速度。会议将分六次举行。第一次会议将审查谷氨酸介导的信号传导的基本方面的最新进展，并提出解剖学，电生理学和信号转导的观点之间的相互作用单胺系统，长期的重点研究精神疾病，谷氨酸系统。接下来的四次会议将围绕特定的疾病组织。会议将以谷氨酸为基础的药物治疗精神分裂症和成瘾等疾病的会议结束。除了全体会议外，还将在两个下午举行海报展示会。

DESCRIPTION (provided by applicant): Although glutamate-mediated neurotransmission has long been implicated in neurodegenerative disorders, the major focus of research on cognitive, affective and addictive disorders has been on monoamine(dopamine, serotonin, norepinephrine) systems in the brain. Because of glutamate's importance in cortical function, and because glutamatergic projections govern the activity of monoaminergic neurons, studies on the possible role of glutamate in affective and addictive disorders began 10-15 years and have led to significant advances in our understanding of glutamatergic involvement in these disorders. The New York Academy of Sciences is sponsoring a 2.5 day conference, scheduled for April 13-15, 2003, in New Haven, CT, titled "Glutamate and Disorders of Cognition and Motivation" The objective is to bring together diverse groups of basic and clinical researchers who study the role of glutamate in cognitive disorders such as schizophrenia, and disorders relating to motivation and affect, such as depression and addiction. This conference will provide a venue for presentation of cutting edge research in both basic and clinical fields. By facilitating interactions between basic scientists and clinicians, it may accelerate the rate at which advances in our knowledge of basic mechanisms can be translated into development of new pharmacotherapies. The conference will be organized in six sessions. The first session will review recent advances in basic aspects of glutamate-mediated signaling and present anatomical, electrophysiological and signal transduction perspectives on interactions between monoamine systems, long the focus of research on psychiatric disorders, and glutamate systems. The next four sessions will be organized around specific disorders. The meeting will close with a session on glutamate-based pharmacotherapies for disorders ranging from schizophrenia to addiction. In addition to the plenary sessions, poster sessions will be held on two afternoons.